Mark R Albertini, MD
University of Wisconsin, Madison
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark R Albertini, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:23 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03958383 · IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaUniversity of Wisconsin, Madison · terminated · Melanoma · study chair
- Ph2NCT00590824 · Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV MelanomaUniversity of Wisconsin, Madison · completed · Melanoma · study chair
- Ph2NCT00109863 · Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced MelanomaUniversity of Wisconsin, Madison · completed · Melanoma (Skin) · study chair
- Ph1NCT00003897 · Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant MelanomaUniversity of Wisconsin, Madison · completed · Melanoma (Skin) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Programmatic Meeting for Surveillance, Epidemiology, and End Results (SEER) - Wisconsin Dept Health Sciences26120180001 · NCI · WISCONSIN DEPARTMENT OF HEALTH SERVICES · fiscal years 2018 · $1,208 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PAUL M SONDEL · fiscal years 2015 to 2021Named on NCT03958383
- Clinical Development of HU14.18-IL2 Targeted TherapyR01CA032685 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PAUL M SONDEL · fiscal years 2011 to 2014Named on NCT00590824, NCT00109863
- Drug Development CoreP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI TIMOTHY S BUGNI · fiscal years 2011 to 2026Named on NCT00109863
- U01CA061498RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00003897
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.